Iodine i 131 apamistamab is a Monoclonal Antibody Conjugated owned by Actinium Pharmaceuticals, and is involved in 10 clinical trials, of which 8 were completed, and 2 are ongoing.

Iomab-B (BC8-I-131 construct) target CD45, a pan-leukocytic antigen widely expressed on white blood cells. BC8 carries radioactivity directly to the site of cancerous growth while avoiding effects of radiation on most healthy tissues. BC8 targets and eradicate cancerous and other white blood cells in preparation for a hematopoietic stem cell transplantation. BC8 delivers I131 isotope directly to the target cells and avoids effects of radiation on most healthy tissues. The drug candidate enhances cytotoxicity in all cell lines. Thus, Iomab-B could be effective against blood cancer such as relapsed/refractory acute myelocytic leukemia (AML), Hodgkin lymphoma, myelodysplastic syndrome and non-Hodgkin lymphoma.

The revenue for Iodine i 131 apamistamab is expected to reach a total of $685m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iodine i 131 apamistamab NPV Report.

Iodine i 131 apamistamab was originated by Fred Hutchinson Cancer Research Center and is currently owned by Actinium Pharmaceuticals.

Iodine i 131 apamistamab Overview

Iomab-B, a radioimmunoconjugate (BC8-I-131 construct) is under development for the treatment of relapsed and refractory follicular lymphoma, chronic lymphocytic leukemia, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, relapsed and refractory B-cell acute lymphoblastic leukemia and chronic myeloid leukemia (CML), acute myelocytic leukemia (AML), HIV-related lymphoma, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative disorders, relapsed and/or refractory elderly acute myeloid leukemia,chronic myelomonocytic leukaemia, refractory anemia with excess blasts, cytopenia, multiple myeloma and refractory anemia with ringed sideroblasts and for prevention of lymphodepletion during CAR-T therapy. The drug candidate is also under development for bone marrow conditioning before a hematopoietic stem cell transplant (HSCT), in relapsed/refractory elderly AML patients. It is administered intravenously. Iomab-B consists of the monoclonal antibody apamistamab and the beta emitting radioisotope I131 (I-131). It acts by targeting CD45 and is developed by using Alpha Particle Immunotherapy (APIT) platform. It was also under development for Hodgkin lymphoma, relapsed/refractory B-non-Hodgkin lymphoma (B-NHL), T-non-Hodgkin lymphoma(T-NHL) and mantle cell lymphoma, 

Actinium Pharmaceuticals Overview

Actinium Pharmaceuticals (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company’s pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE Technology Platform. It develops products to treat colon, prostrate and brain cancer. ATNM is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$25 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$24.8 million in FY2021, compared to a net loss of US$22.2 million in FY2020.

Quick View – Iodine i 131 apamistamab

Report Segments
  • Innovator
Drug Name
  • Iodine i 131 apamistamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.